Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jacob J. Clement is active.

Publication


Featured researches published by Jacob J. Clement.


Biochemical and Biophysical Research Communications | 1991

Potent HIV-1 protease inhibitors with antiviral activities in vitro

Hing L. Sham; David A. Betebenner; Norman E. Wideburg; Ayda Saldivar; William E. Kohlbrenner; Sudthida Vasavanonda; Dale J. Kempf; Daniel W. Norbeck; Chen Zhao; Jacob J. Clement; John E. Erickson; Jacob J. Plattner

A series of novel difluoroketones with low molecular weight (less than 600 m.u.) and which are potent inhibitors of the HIV-1 protease (IC50 = 1.0 to 21 nM) were synthesized. These compounds also exhibited antiviral activity by inhibition of the cytopathic effect of HIV-1(3)B in MT-4 cells in vitro.


Antiviral Research | 1994

Efficacy of A-73209, a potent orally active agent against VZV and HSV infections

Jeffrey Alder; Michael J. Mitten; Dan Norbeck; Kennan Marsh; Earl R. Kern; Jacob J. Clement

A-73209 is a novel oxetanocin derivative with potent in vitro and in vivo activity against VZV, HSV-1, and HSV-2. A-73209 was two logs more potent than acyclovir against five thymidine kinase positive (TK+) strains of VZV in vitro (mean EC50 0.01 vs. 1.22 micrograms/ml). The activity of A-73209 was one log more potent than acyclovir against TK+ HSV-1 strains in vitro (EC50 = 0.03 vs. 0.32 micrograms/ml). A-73209 yielded a mean EC50 of 2.2 micrograms/ml compared to a mean EC50 of 0.37 micrograms/ml for acyclovir against a panel of TK+ HSV-2 strains in vitro. The in vitro activity of A-73209 against thymidine kinase negative or deficient strains of VZV, HSV-1 and HSV-2 was much lower than for the corresponding TK+ strains. A-73209 produced efficacy superior to acyclovir against lethal systemic or intracerebral HSV-1 infections in mice. The greater efficacy of A-73209 relative to acyclovir was especially apparent with oral dosing. Against HSV-2 infections in mice, the efficacy of A-73209 ranged from equal to 1.7 times less active relative to acyclovir with oral dosing. A-73209 was orally bioavailable in mice, with maximal serum concentrations well in excess of in vitro inhibitory concentrations. A-73209 appears to be a potent and selective agent against varicella-zoster virus and herpes simplex virus infections.


FEBS Letters | 1993

Pseudo-symmetrical difluoroketones: Highly potent and specific inhibitors of HIV-1 protease

Hing L. Sham; David A. Betebenner; Norman E. Wideburg; Ayda Saldivar; William Kohlbrenner; Adrienne Craig-Kennard; Sudthida Vasavanonda; Dale J. Kempf; Jacob J. Clement; John E. Erickson; Jacob J. Plattner; Daniel W. Norbeck

A series of novel, pseudo‐symmetrical difluoroketones which are highly potent inhibitors of the HIV‐1 protease (IC50 = 1.55‐0.02 nM) were synthesized. These compounds also possess good antiviral activity by inhibition of the cytopathic effect of HIV‐13B in MT‐4 cells in vitro.


Journal of Medicinal Chemistry | 1990

Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS.

Daniel W. Norbeck; Earl R. Kern; Seiji Hayashi; William Rosenbrook; Hing L. Sham; Thomas Herrin; Jacob J. Plattner; John W. Erickson; Jacob J. Clement; Robert N. Swanson; Nathan L. Shipkowitz; Dwight J. Hardy; Kennan Marsh; Gussie Arnett; William M. Shannon; Samuel Broder; Hiroaki Mitsuya


The Journal of Antibiotics | 1996

Novel triterpene sulfates from Fusarium compactum using a rhinovirus 3C protease inhibitor screen.

Gregory M. Brill; Warren M. Kati; Debra Montgomery; James P. Karwowski; Patrick E. Humphrey; Marianna Jackson; Jacob J. Clement; Sunil Kadam; Randal H. Chen; James B. McAlpine


Journal of Medicinal Chemistry | 1991

SYNTHESIS AND ANTITUMOR ACTIVITY OF STRUCTURAL ANALOGUES OF THE EPIPODOPHYLLOTOXINS

Larry L. Klein; Clinton M. Yeung; Daniel T. Chu; Edith McDonald; Jacob J. Clement; Jacob J. Plattner


The Journal of Antibiotics | 1992

Synthesis and activity of C-21 alkylamino derivatives of (9R)-erythromycylamine.

Paul A. Lartey; Shari L. DeNinno; Ramin Faghih; Dwight J. Hardy; Jacob J. Clement; Jacob J. Plattner


The Journal of Antibiotics | 1996

Discovery of saricandin, a novel papulacandin, from a Fusarium species

Randal H. Chen; Shaun Tennant; David J. Frost; Michael J. O'Beirne; James P. Karwowski; Patrick E. Humphrey; Li Hong Malmberg; Won Choi; Kim Brandt; Paul West; Sunil Kadam; Jacob J. Clement; James B. McAlpine


Journal of Antimicrobial Chemotherapy | 1994

Treatment of experimental Pneumocystis carinii infection by combination of clarithromycin and sulphamethoxazole

Jeffrey Alder; Michael J. Mitten; Nate Shipkowitz; Lisa E. Hernandez; Yu-hua Hui; Kennan Marsh; Jacob J. Clement


Canadian Journal of Chemistry | 1992

Syntheses and antibacterial activity of novel 6-fluoro-7-(gem-disubstituted piperazin-1-yl)-quinolines

Daniel T. W. Chu; Akiyo Claiborne; Jacob J. Clement; Jacob J. Plattner

Collaboration


Dive into the Jacob J. Clement's collaboration.

Top Co-Authors

Avatar

Daniel W. Norbeck

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Dwight J. Hardy

University of Rochester Medical Center

View shared research outputs
Top Co-Authors

Avatar

Hing L. Sham

Thermo Fisher Scientific

View shared research outputs
Top Co-Authors

Avatar

Dale J. Kempf

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

James B. McAlpine

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gussie Arnett

Southern Research Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge